Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme. A ...
MIDLOTHIAN, Va., May 7, 2020 /PRNewswire/ -- This week, the first patients are enrolling in two phase 2 clinical trials for COVID-19 using Pulmotect's PUL-042, an inhaled immunomodulatory agent to ...
As highlighted in the April issue of Medical Device & Diagnostic Industry magazine, PARI Aerosol Research Institute has been awarded a 2006 Medical Design Excellence Award for eFlow. eFlow is an ...
- ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options - ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback